Read this company snapshot
Daily valuation snapshot
Oculis Holding AG Ordinary shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $8.34
- Market capitalization (USD)
- $513,644,528.82
- Price / earnings (TTM)
- Not reported
- Price / book
- 2.08
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research OCS in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research OCS in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing OCS with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $8.34 |
| Market capitalization (USD) | $513,644,528.82 |
| Price / earnings (TTM) | Not reported |
| Price / book | 2.08 |
No matching rows. Clear the filter to see all records.
Read OCS's valuation metrics
Company size
Oculis Holding AG Ordinary shares's recorded market capitalization is $513,644,528.82. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
OCS's recorded price-to-book ratio is 2.08. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Oculis Holding AG Ordinary shares with Aurora
Use the snapshot above to ask a specific question about OCS. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow OCS's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.